Beta Finch - AbbVie - ABBV - EN

# Beta Finch Podcast Script: AbbVie Q1 2026 Earnings**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, and I'm here with my co-host Jordan to dive into AbbVie's first quarter 2026 results. **JORDAN**: Hey everyone! Before we jump in, we need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**ALEX**: Absolutely. Now Jordan, AbbVie just delivered what I'd call a knockout quarter. They beat expectations across the board and raised guidance - what stood out to you first?**JORDAN**: The numbers are impressive, Alex. They hit $2.65 in adjusted earnings per share, which was 7 cents above their guidance midpoint. But what really caught my eye was that revenue growth - 12.4% to $15 billion, beating expectations by $300 million. That's some serious momentum.**ALEX**: And they're not just celebrating - they're doubling down. They raised their full-year EPS guidance by 12 cents to between $14.08 and $14.28. What's driving this confidence?**JORDAN**: Two words: Skyrizi and immunology. Skyrizi alone pulled in $4.5 billion in sales, up over 29% operationally. CEO Robert Michael specifically called out the "momentum in immunology and neuroscience" with both segments gaining market share in growing markets. This isn't just about riding a wave - they're creating it.**ALEX**: The Skyrizi story is fascinating because it shows how a well-positioned drug can dominate even in a competitive landscape. Jeff Stewart, their commercial head, mentioned they have "over 4x basically the in-play share" versus their next competitor. How sustainable is that kind of dominance?**JORDAN**: That's the million-dollar question, Alex. They're facing new competition, including an oral competitor that launched recently. But Stewart seemed pretty confident during the Q&A, pointing to their head-to-head trials across five different mechanisms in psoriasis, superior durability data, and that convenient quarterly dosing. He even suggested the oral competition might expand the market rather than just steal share.**ALEX**: Speaking of competition, one analyst specifically asked about competitive pressure, and I found Stewart's response really telling. He basically said their audit data shows NBRx - new prescriptions - hitting all-time highs despite having incredibly high market share already. That suggests real physician preference, not just early adoption.**JORDAN**: Exactly. And they're not just defending Skyrizi - they're expanding it. The subcutaneous induction data for Crohn's disease looked impressive. Dr. Roopal Thakkar highlighted that in treatment-naive patients, 61% achieved endoscopic response and 73% achieved clinical remission. Those are some serious numbers.**ALEX**: But here's where it gets really interesting - their combination strategy. Tell our listeners about this Skyrizi plus alpha-4 beta-7 antibody data.**JORDAN**: This is potentially game-changing, Alex. In their platform study, the combination doubled the endoscopic remission rate compared to either drug alone - about 42% of patients at week 24. And remember, this was in severely refractory patients where 82% had failed advanced treatments. Thakkar called it "potentially transformative efficacy."**ALEX**: The R&D pipeline seems to be the real story here. They're not just maintaining current success - they're building the next generation. What else caught your attention?**JORDAN**: Their obesity program is heating up. The early data on ABBV-295, their long-acting amylin analog, showed nearly 10% weight loss in just 12 weeks. In a predominantly male, non-obese population, no less. With a 270-hour half-life, they're talking about potential monthly dosing, which could be huge for patient compliance.**ALEX**: And let's not forget neuThis episode includes AI-generated content.